Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations

American Heart Journal

Volumn 168, Issue 5, 2014, Pages 698-705.e2

  Jeger, Raban V ^a   Pfisterer, Matthias E ^a   Sørensen, Rikke ^b   Von Felten, Stefanie ^a   Alber, Hannes ^c   Bonetti, Piero O ^d   Eberli, Franz ^e   Erne, Paul ^f   Pedrazzini, Giovanni ^g   Rickli, Hans ^h   Galatius, Søren ^b   Kaiser, Christoph A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^e TRIEMLI HOSPITAL   (Switzerland)

^f LUZERNER KANTONSSPITAL   (Switzerland)

^g DIVISION OF CARDIOLOGY   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; RAPAMYCIN; TICLOPIDINE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DUAL ANTIPLATELET THERAPY; FATALITY; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POST TREATMENT SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; ANGINA PECTORIS; CHEMICALLY INDUCED; CONTROLLED STUDY; CORONARY THROMBOSIS; DRUG COMBINATION; DRUG ELUTING STENT; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TIME;

AGED; ANGINA PECTORIS; ASPIRIN; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS FAILURE; RISK ASSESSMENT; SIROLIMUS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908323403     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.07.019     Document Type: Article

References (32)

1. M.B. Leon, D.S. Baim, and J.J. Popma A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators N Engl J Med 339 23 1998 1665 1671
2. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 24 2011 e44 e122
3. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization Eur Heart J 31 20 2010 2501 2555
4. F. Airoldi, A. Colombo, and N. Morici Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment Circulation 116 7 2007 745 754
5. S. Schulz, T. Schuster, and J. Mehilli Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period Eur Heart J 30 22 2009 2714 2721
6. C. Kaiser, S. Galatius, and P. Erne Drug-eluting versus bare-metal stents in large coronary arteries N Engl J Med 363 24 2010 2310 2319
7. G.G. Stefanini, B. Kalesan, and P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 9807 2011 1940 1948
8. H.C. Gwon, J.Y. Hahn, and K.W. Park Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 3 2012 505 513
9. M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 16 2012 2015 2026
10. F. Feres, R.A. Costa, and A. Abizaid Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 23 2013 2510 2522
11. D.E. Kandzari, C.S. Barker, and M.B. Leon Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents JACC Cardiovasc Interv 4 10 2011 1119 1128
12. C. Kaiser, H.P. Brunner-La Rocca, and P.T. Buser Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET) Lancet 366 9489 2005 921 929
13. L. Mauri, W.H. Hsieh, and J.M. Massaro Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 10 2007 1020 1029
14. M. Pfisterer, O. Bertel, and P. Bonetti Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design Am Heart J 155 4 2008 609 614
15. H.P. Brunner-La Rocca, C. Kaiser, and M. Pfisterer Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET) Eur Heart J 28 6 2007 719 725
16. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group N Engl J Med 312 14 1985 932 936
17. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 23 2011 2736 2747
18. D. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 17 2007 2344 2351
19. S.C. Smith Jr., T.E. Feldman, and J.W. Hirshfeld Jr. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) Circulation 113 7 2006 e166 e286
20. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
21. D.E. Cutlip, D.S. Baim, and K.K. Ho Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials Circulation 103 15 2001 1967 1971
22. I. Moussa, C. Di Mario, and B. Reimers Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome J Am Coll Cardiol 29 1 1997 6 12
23. G.J. Karrillon, M.C. Morice, and E. Benveniste Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry Circulation 94 7 1996 1519 1527
24. J.L. Orford, R. Lennon, and S. Melby Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry J Am Coll Cardiol 40 9 2002 1567 1572
25. I. Iakovou, T. Schmidt, and E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 17 2005 2126 2130
26. J.W. van Werkum, A.A. Heestermans, and F.I. de Korte Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases Circulation 119 6 2009 828 834
27. T. Kimura, T. Morimoto, and K. Kozuma Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) Circulation 122 1 2010 52 61
28. L. Räber, M. Magro, and G.G. Stefanini Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study Circulation 125 9 2012 1110 1121
29. S. Subherwal, R.G. Bach, and A.Y. Chen Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score Circulation 119 14 2009 1873 1882
30. R.A. Byrne, S. Schulz, and J. Mehilli Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study Am Heart J 157 4 2009 620-4.e2
31. L. Mauri, D.J. Kereiakes, and S.L. Normand Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions Am Heart J 160 6 2010 1035 1041 [1041.e1]
32. M. Pfisterer, C. Kaiser, and R. Jeger No one-size-fits-all: a tailored approach to antithrombotic therapy after stent implantation Circulation 125 3 2012 471 473